Clinical Trial Update: Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer (ImmunoSABR) [Phase 2]

View source ↗

Summary

A Phase 2 trial (ImmunoSABR) combining SABR and L19-IL2 for stage IV non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• L19-IL2 (Interleukin-2 fused to the L19 antibody (L19-IL2))
• SABR

Snippet

Sponsor: Maastricht Radiation Oncology | Conditions: NSCLC Stage IV, Limited Metastatic Disease | Phase 2 | Status: WITHDRAWN